EPA:ALINT - Euronext Paris - Matif - FR0010908723 - Common Stock - Currency: EUR
EPA:ALINT (5/13/2025, 7:00:00 PM)
0.6
-0.01 (-1.62%)
The current stock price of ALINT.PA is 0.6 EUR. In the past month the price increased by 18.81%. In the past year, price decreased by -6.25%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 18.18 | 297.54B | ||
AMG.DE | AMGEN INC | 12.96 | 130.25B | ||
1GILD.MI | GILEAD SCIENCES INC | 13.27 | 115.15B | ||
GIS.DE | GILEAD SCIENCES INC | 13.07 | 113.46B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | N/A | 100.74B | ||
1REGN.MI | REGENERON PHARMACEUTICALS | 11.72 | 52.64B | ||
ARGX.BR | ARGENX SE | 101.39 | 29.84B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 20.71B | ||
IDP.DE | BIOGEN INC | 7.71 | 16.10B | ||
1MRNA.MI | MODERNA INC | N/A | 8.90B | ||
0QF.DE | MODERNA INC | N/A | 8.88B | ||
BIO.DE | BIOTEST AG | 65.54 | 1.69B |
IntegraGen SA engages in the development of genetic biomarkers. The company is headquartered in Evry, Ile-De-France. The company went IPO on 2010-06-18. The company researches and develops biomarkers for use as diagnostic tools in the fields of autism, oncology, diabetes and obesity. The company uses an evaluation model with several autism-related genes using a combination of several common polymorphisms (Single-Nucleotide Polymorphism or SNP or common variant). The company also develops molecular biomarker validation programs for Hepatocellular Carcinoma and anti-epidermal growth factor receptor (anti-EGFR) resistance markers. The firm also provides genomics services to practitioners and researchers, such as DNA extraction, marker selection and tagging and bioinformatical analysis of sequence data in such fields as pharmacogenetics, cytogenetics, epigenetics, search for mutations and SNP discovery, among others. As of December 31, 2011, the Company operated through a wholly owned subsidiary, IntegraGen Inc.
INTEGRAGEN
Genopole Campus 1 - Genavenir 8 5 Rue Henri Desbrueres
Evry ILE-DE-FRANCE FR
Employees: 44
Phone: 33160910900
The current stock price of ALINT.PA is 0.6 EUR. The price decreased by -1.62% in the last trading session.
The exchange symbol of INTEGRAGEN is ALINT and it is listed on the Euronext Paris - Matif exchange.
ALINT.PA stock is listed on the Euronext Paris - Matif exchange.
INTEGRAGEN (ALINT.PA) has a market capitalization of 4.04M EUR. This makes ALINT.PA a Nano Cap stock.
INTEGRAGEN (ALINT.PA) currently has 44 employees.
INTEGRAGEN (ALINT.PA) has a support level at 0.57 and a resistance level at 0.61. Check the full technical report for a detailed analysis of ALINT.PA support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ALINT.PA does not pay a dividend.
ChartMill assigns a technical rating of 8 / 10 to ALINT.PA. When comparing the yearly performance of all stocks, ALINT.PA turns out to be only a medium performer in the overall market: it outperformed 63.05% of all stocks.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | N/A | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 87% to ALINT.PA. The Buy consensus is the average rating of analysts ratings from 9 analysts.